For ViiV Healthcare—the HIV-focused joint venture between GSK, Pfizer and ... research and community work, and also to use that as evidence of how far we can go to end HIV,” Pierre said ...
GSK’s ViiV ... by the end of December. The company is a joint venture majority owned by GlaxoSmithKline, with Pfizer and Shionogi as shareholders, and is attempting to develop HIV drugs that ...
which can prevent permanent HIV infection According to Reuters, ViiV, a joint venture between GSK, Pfizer and Shionogi, is developing the first injectable PrEP treatment in collaboration with US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback